Lonza has applied its 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months.

This presentation from PEGS Boston 2022 highlights key approaches and technologies that enable this timeline.

Case study examples will be shared for application in vector, process, analytic and formulation development of bispecific molecules during pre-clinical development.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center